Literature DB >> 20022634

Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.

Said I Ismail1, Ismail S Mahmoud, Mohammed M Msallam, Maher A Sughayer.   

Abstract

The phosphatidylinositol-3-kinases PI3K/AKT pathway regulates many growth and survival mechanisms in the cell, and it has been implicated in development and progression of many human cancers, including multiple myeloma. Recently, many reports have revealed that the PIK3CA gene which encodes the p110 catalytic subunit of PI3K kinase is mutated in many human malignancies. To investigate the oncogenic role of PI3K/AKT pathway in multiple myeloma we sequenced three hot exons: exons 9 and 20 of PIK3CA gene and exon 3 of AKT1 gene in 27 multiple myeloma patients. Our results indicate the absence of the four hot spot mutations E542K, E545K, H1047R and E17K in all studied cases. These findings suggest that PI3K/AKT mutations may not play a major role in multiple myeloma. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022634     DOI: 10.1016/j.leukres.2009.11.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

Review 1.  Signaling Pathways and Emerging Therapies in Multiple Myeloma.

Authors:  Vijay Ramakrishnan; Anita D'Souza
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 2.  Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

Authors:  Yanan Gao; Chase Y Yuan; Weiping Yuan
Journal:  Stem Cell Investig       Date:  2016-07-22

3.  Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.

Authors:  Vishwanathan Hucthagowder; Rekha Meyer; Chelsea Mullins; Rakesh Nagarajan; John F DiPersio; Ravi Vij; Michael H Tomasson; Shashikant Kulkarni
Journal:  Cancer Genet       Date:  2012-09

4.  Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations.

Authors:  J Glassford; D Kassen; J Quinn; C Stengel; K Kallinikou; A Khwaja; K L Yong
Journal:  Blood Cancer J       Date:  2012-01-13       Impact factor: 11.037

5.  Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.

Authors:  C Stengel; C W Cheung; J Quinn; K Yong; A Khwaja
Journal:  Leukemia       Date:  2012-03-14       Impact factor: 11.528

6.  Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.

Authors:  Stefan Hausmann; Evelyn Brandt; Carolin Köchel; Hermann Einsele; Ralf C Bargou; Ruth Seggewiss-Bernhardt; Thorsten Stühmer
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

7.  Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.

Authors:  I Sahin; M Moschetta; Y Mishima; S V Glavey; B Tsang; F Azab; S Manier; Y Zhang; P Maiso; A Sacco; A K Azab; A M Roccaro; I M Ghobrial
Journal:  Blood Cancer J       Date:  2014-04-25       Impact factor: 11.037

8.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

9.  p110δ PI3 kinase pathway: emerging roles in cancer.

Authors:  Niki Tzenaki; Evangelia A Papakonstanti
Journal:  Front Oncol       Date:  2013-03-01       Impact factor: 6.244

10.  Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.

Authors:  Vijay Ramakrishnan; Teresa Kimlinger; Jessica Haug; Utkarsh Painuly; Linda Wellik; Timothy Halling; S Vincent Rajkumar; Shaji Kumar
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.